At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 50 enrolled
Drug / intervention
Methyl Aminolaevulinate 16% Creamdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Subject Reported Outcomes on Satisfaction, Safety and Efficacy With Luxerm® in the Field-directed Treatment of Thin or Non-hyperkeratotic and Non-pigmented Actinic Keratosis of the Face or the Scalp
In Brief
A Phase 4 clinical trial evaluating Methyl Aminolaevulinate 16% Cream for Actinic Keratoses. Completed, enrolled 50 participants across 1 site.
Detailed Summary
Interventional open label prospective and multicentre study conducted in Germany in subjects with thin or non-hyperkeratotic and non-pigmented multiple AKs in one anatomical area on the face (e.g., forehead or cheek or chin), excluding nose eyelids, lips and mucosa or balding scalp, using Luxerm® DL-PDT treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsActinic Keratoses
CountriesGermany
Collaborators--
Timeline
Phase 4CompletedFinished
201820192020202120222023202420252026
Enrollment StartJun 2017
Primary CompletionNov 2017
First PostedApr 2018
TodayJul 2026
First PostedApr 27, 2018
Enrollment StartJun 7, 2017
Primary CompletionNov 28, 2017
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 8.2 years ago
Interventions
Methyl Aminolaevulinate 16% Creamdrug
Subject will received one session of methyl aminolevulinate Daylight Photodynamic therapy